References
- Ferreri AJ, Batchelor T, Zucca E, et al. International collaborative group against primary CNS lymphomas. J Clin Oncol. 2003;21:1649–1650.
- Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–272.
- Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410–2418.
- Plotkin SR. Update on primary central nervous system lymphoma. Curr Opin Neurol. 2005;18:645–653.
- Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49:43–51.
- Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20:687–694.
- Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715.
- Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am. 2005;19:629–649.
- Levitt LJ, Dawson DM, Rosenthal DS, et al. CNS involvement in the non-Hodgkin’s lymphomas. Cancer. 1980;45:545–552.
- O’Neill BP, Dinapoli RP, Kurtin PJ, et al. Occult systemic non-Hodgkin’s lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neuro-Oncol. 1995;25:67–71.
- Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54:854–859.
- Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504–1510.
- Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–5043.
- Ferreri AJ, Reni M, Zoldan MC, et al. Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion. Cancer. 1996;77:827–833.
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994.
- Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.
- Karantanis D, O’Neill BP, Subramaniam RM, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med. 2007;32:271–274.
- Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10:223–228.
- DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol. 2002;20:4643–4648.
- Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118:510–522.
- Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–4651.
- Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
- Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol. 1999;43:231–236.
- Zou Y, Tong J, Leng H, et al. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: a systematic review and meta-analysis. Oncotarget. 2017;8:41518–41528.
- Pollack IF, Lunsford LD, Flickinger JC, et al. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer. 1989;63:939–947.